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Introduction: A pathologic grading system (PGS) for ma-
lignant pleural mesothelioma (MPM) is warranted to better
identify different risk categories of patients, plan thera-
peutic options, and activate clinical trials.
Methods: A series of 940 patients with MPM (328 in a
training set and 612 in a validation set) that was diagnosed
between October 1980 and June 2015 at the participant
institutions was retrospectively assembled. A PGS was
constructed by attributing to each histologic parameter,
independent at multivariate analysis with excellent
reproducibility (k > 0.75), different scores based on the
increase in corresponding hazard ratios. The relevant PGS
score thus ranged from 0 to 8 points for individual patients
with MPM.
Conclusions: The PGS was constructed by taking into
consideration the histological subtyping of MPM (epithe-
lioid/biphasic ¼ 0 points; sarcomatoid ¼ 2 points), necrosis
(absent ¼ 0 points versus present ¼ 1 point), mitotic count
per 1 mm2 (cutoffs as follows: 1–2 ¼ 0 points, 3–5 ¼ 1
point, 6–9 ¼ 2 points, or 10 ¼ 4 points), and Ki-67 la-
beling index based on 2000 cells (<30% ¼ 0 points versus
30 ¼ 1 point), all of which are independent factors in both
patient sets after adjustment for stage and age at diagnosis.
No heterogeneity was seen across the validation centers
(p ¼ 0.19). Epithelioid/biphasic MPM patterning and biopsy
versus resection did not affect survival, whereas the PGS
outperformed mitotic count and Ki-67 LI in both the
training (area under the curve receiver operating
characteristic ¼ 0.76) and validation sets (area under the
curve receiver operating characteristic ¼ 0.73) (p < 0.01).
Patient survival progressively deteriorated from a score of
0 (median times of 26.3 and 26.9 months) to a score 1 to 3
(median times of 12.8 and 14.4 months) and a score of 4 to
8 (median times of 3.7 and 7.7 months) in both sets of
patients, with the hazard ratio for a 1-point increase in
score being 1.46 (95% confidence interval: 1.36–1.56) in
the training set and 1.28 (95% confidence interval: 1.22–
1.34) in the validation set (after adjustment for age and
[when available] tumor stage). The PGS was effective even
in subgroup analysis (epithelioid, biphasic, and sarcomatoid
tumors).
Discussion: A simple and reproducible multiparametric
PGS effectively predicted survival in patients with MPM.
 2018 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.Keywords: Mesothelioma; Pleura; Grading; Survival; Score
Introduction
Malignant pleural mesothelioma (MPM) is a rare
and aggressive neoplasm with ominous prognosis
quoad vitam and quoad valetudinem, the incidence of
which has been steadily increasing worldwide and
leveling off in Western countries.1–5 Epithelioid
(EMPM), biphasic (BMPM), and sarcomatoid (SMPM)
mesothelioma account for the main histologic vari-
ants,6,7 with EPMPs likely to behave less aggressively in
comparison with BMPMs and especially in comparison
with SMPMs.8–10 Few studies have supported the
notion that EMPM patterns can actually affect sur-
vival,11–13 although the pleomorphic variant is thought
to be an independent predictor of a dismal
prognosis.11,14
A constellation of factors has been adopted in the
clinical management of patients with MPM,2,8,9,15–18
especially in cases of young subjects with early-stage
disease, good performance status, and the epithelioid
histologic variant.1,2,19 These patients account for most
of the 15% to 20% of patients with MPM who survive
more than 3 years8,11,14,20–22 and in whom a more
aggressive treatment is clinically warranted.1,23,24 It is
tempting, however, to speculate about how quickly the
disease will evolve at the level of an individual patient’s
cancer after the initial morphologic diagnosis.8,15,16,23,25
Several investigations have confirmed that MPMs, as
well as their peritoneal counterpart, encompass a
case mix of diversely behaving tumors, with more
indolent lesions being recorded within the epithelioid
variant (also because of an earlier stage of dis-
ease).2,8,11,13,21,22,26–29 Although most patients with MPM
relentlessly die of illness over time, treatments are
generally decided on the basis of managerial clinical
criteria in which pathologic grading does not yet play an
established role.1,2
A concept of grading in patients with MPM is
included in the current WHO histologic classification,6,7
although recent proposals have credited a role to
nuclear atypia,22,30 mitotic count,22,30 or Ki-67 antigen
labeling index (LI),21 at least in the epithelioid variant,
with similar results being described in the peritoneum.26
Other studies have focused on necrosis, nucleolus pres-
ence and size, atypical mitoses, or growth patterns as
--- 2018 Grading Malignant Pleural Mesothelioma 3grading criteria.13,30 Ideally, a grading system should
offer timely prognostic information for individual pa-
tients with MPM regardless of the therapy being
administered, the type or size of the diagnostic material,
and histologic appearance. Grading could also assist cli-
nicians in assigning patients to different outcomes,
planning of individualized treatments, follow-up strate-
gies, and clinical trial design. Knowledge of tumor
aggressiveness is clinically beneficial to providing the
right drug to the right patient at the right time.1,19
This large multi-institutional study was designed to
develop and validate an innovative and reproducible
subtyping score that is readily evaluable by clinicians
and based solely on the evaluation of common and
reproducible histopathologic parameters.Materials and Methods
Patients with Tumors
A large multicenter, retrospective, observational
study including 940 consecutive patients with a diag-
nosis of MPM based on either biopsy or resection spec-
imens and follow-up information spanning from October
1980 to June 2015 was undertaken at the participating
institutions. The challenge was to construct an innova-
tive pathologic grading system (PGS) by using common
and easy-to-assess histologic criteria to reliably predict
tumor behavior for different kinds of patient cancers.
Five secondary or tertiary Italian independent in-
stitutions that are devoted to and leaders in the diag-
nosis and treatment of MPM took part in the study. One
center (the Bari set) contributed 328 patients to the
training cohort, and four centers (the Milan, Modena,
Padua, and Turin sets) contributed 612 patients to the
validation cohort. Part of the Padua case series (24
cases) came from the Golnik Center (Slovenia), which is
another center devoted to the diagnosis and treatment of
this kind of tumor. These cases were in part processed in
Padua (for Ki-67 antigen immunostaining) and addi-
tionally used for the validation cohort (data not shown).
The main demographic and clinicopathologic character-
istics of the patients in the training and validation
cohorts are presented in Table 1.
All the original histologic slides were reviewed by
two pathologists experienced in MPM from each center
to ensure diagnostic consistency; they were blinded to
patient identity and initial tumor categorization. Infor-
mation about demography, asbestos exposure, cancer-
related overall survival (OS), tumor staging, adjuvant
and/or neoadjuvant therapy, and types of material
(a small biopsy specimen if the tumor measured 2 cm
on gross examination; a large biopsy if the tumor
measured >2 cm or pleurectomy was performed; and a
surgical resection specimen if major surgical procedureswere carried out) was obtained from the original pa-
thology reports, clinical charts, referring physicians, the
patients, and their families. These data were subse-
quently collected in a database.
Tumor tissues were fixed in a 4% buffered formal-
dehyde solution for 12 to 24 hours and embedded in
paraffin according to the standard histopathologic
methods. All diagnoses were also supported by appro-
priate immunohistochemistry according to current
guidelines (two mesothelial markers and two carcinoma
cell markers).31 A list of commonly assessed histologic
parameters was tested in the training set for devising the
PGS. They included percentage of necrosis on the whole
tumor tissue specimens present on slides; tumor sub-
typing according to the 2015 WHO classification7;
growth patterning of the EMPM or the epithelioid
component of the BMPM assessed; cell atypia of the
EMPM or the epithelioid component of the BMPM, which
was classified as mild, moderate, or severe according to
the resemblance of tumor cells in terms of nuclear shape
and size and discernible amount of cytoplasm with
nonneoplastic mesothelial cells within each tumor case;
nucleoli (inconspicuous, distinct, macronucleoli); mitotic
count per 1 mm2 evaluated in representative tumor
blocks by scanning preserved tumor areas with the
highest activity after scrutiny of all available tumor
slides; and Ki-67 LI based on hot spot areas, counting
2000 cells or 1 mm2 in the same tumor block and areas
as for the mitotic count. During evaluation of the Ki-67
LI, particular attention was paid to exclude Ki-67–
decorated inflammatory cells from the final counting by
allowing only pathologists in experienced MPM to
participate in the study. Cutoff points for continuous
variables (i.e., mitotic count and Ki-67 LI) were identified
according to the distribution of individual data across
the training set and then maintained in the validation set.
Furthermore, 128 tumors stemming from the Milan
(79 cases) and Turin (49 cases) sets were reviewed in
blinded fashion by two different pairs of pathologists
for assessing interobserver variability of the histologic
parameters under evaluation.
Ethics
The study was approved by the independent ethics
committee of the Polyclinic Pope John XXIII Hospital,
Bari, Italy (accession number 5062; date June 22, 2016).
All patients gave their written informed consent for
diagnosis and research activities when they were
admitted to the hospital.Statistical Analysis
The main study outcome was OS, which was calcu-
lated from the date of diagnosis of mesothelioma to the
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tions between clinicopathologic characteristics and
patient survival were assessed by using Cox proportional
hazards regression models. The assumption of propor-
tional hazards was verified by visual inspection of the
log of the negative log transformation of the survival
functions for the single covariates included in the
multivariable model. Models were fitted on the whole set
of patients, with missing values represented by dummy
variables (missing indicator method). Pathologic char-
acteristics significantly associated with OS at univariate
analysis and showing good reproducibility (or agree-
ment) between pathologists were selected for inclusion
in the PGS. Agreement between pathologists for the
determination of tumor necrosis, histologic variant,
nucleolus presence, atypia, Ki-67 LI, and mitotic count
was assessed by using the Cohen k: a k value greater
than 0.75 was considered excellent agreement beyond
chance, a k value between 0.40 and 0.75 was considered
good agreement beyond chance, and a k value less than
0.40 was considered poor agreement beyond chance.32
For the sake of simplicity and to allow clinicians to
readily calculate the PGS score, factors with a statistically
significant hazard ratio (HR) less than 2.0 were given 1
point, those with an HR between 2.0 and 4.0 were given
2 points, and those with an HR greater than 4.0 were
given 4 points. The PGS score was obtained by adding up
the points for the four identified factors (i.e., tumor ne-
crosis, histologic variant, Ki-67 LI, and mitotic count).
Survival curves according to the PGS classes (0 point,
1–3 points, and 4–8 points) were constructed by using
the Kaplan-Meier method. Difference in survival between
groups was assessed by the log-rank test. The risk of
death associated with a 1-point increase in the PGS score
was also calculated with adjustment for patients’ age at
diagnosis and tumor stage. We checked for linearity,
plotting b estimates obtained from a model substituting
the continuous PGS for eight dummy variables corre-
sponding to each value of the PGS score and using a b
value of 0 for the reference category. In the training set,
the respective b estimates for PGS scores 0 to 8 were 0,
0.63, 1.22, 1.37, 1.95, 1.98, 2.09, 3.92, and 4.03, indi-
cating a linear relationship. We also assessed the per-
formance of the score with calibration curves, plotting
the observed 12-month mortality with 95% confidence
intervals (CIs) obtained from actuarial survival against
the predicted 12-month mortality derived from the Cox
proportional hazards regression model with PGS score
set as a continuous variable, for groups of patients with
different PGS scores. The predicted 12-month mortality
in the validation cohort was calculated by using the
baseline survival estimate S0 and the covariate estimate
b obtained from the testing set, and it was compared
with the observed mortality in the validation set.We performed stratified analyses based on the whole
set of patients (training plus validation sets) to assess the
validity of the PGS in different patient subgroups. A forest
plot was generated to visually assess the variation of the
HR across all subgroups. Receiver operating characteristic
curves with the respective areas under the curves (AUCs)
were drawn to illustrate the prognostic ability of the PGS
to determine 12-month mortality, set as a binary end
point in comparison with those of Ki-67 LI and mitotic
count when considered alone. Comparison of AUCs was
done by using the nonparametric approach suggested by
DeLong et al.33 We also plotted the time-dependent AUCs,
with 95% CIs in the training cohort and in the validation
cohort for follow-up times ranging from 0 to 60 months,
and we calculated the integrated AUC over time.
All analyses were performed with SAS software
(version 9.4, SAS Institute Inc., Cary, NC). All p values
were two sided, and p values less than 0.05 were
considered statistically significant.Results
Clinicopathologic Traits of Patients
As detailed in Table 1, most patients were male and
older than 60 years in either tumor set, with a slight
prevalence of asbestos exposure and tumors diagnosed
predominantly on the basis of small biopsy specimens
measuring 2 cm or less. Tumor stage information was
available for 39.3% of patients (369 of 940), with an ex-
pected distribution across II to IV stage. Palliative chemo-
therapy had been administered in 68% of patients in the
training set, but only in 39.5% of the those in the validation
set (the set containing the most patients for whom infor-
mation on palliative chemotherapy was missing).
Tumor necrosis was detected in about one-third of
cases in both tumor sets regardless of the amount.
However, EMPMs were prevalent over BMPMs or
SMPMs. EMPMs and the epithelioid component of
biphasic tumors predominantly showed a solid, tubular,
or papillary architecture, whereas SMPMs were mostly
composed of spindled tumor cells, with fewer cases
featuring a desmoplastic or pleomorphic appearance.
Microscopic examination showed inconspicuous to
distinct nucleoli in the nuclear area, whereas eosino-
philic macronucleoli were observed in about one-fourth
of tumors. Tumors featured moderate to severe cell
atypia in 50% or more of cases, with most of them
having a Ki-67 LI greater than 30% and an increased
mitotic count (>3 mitoses per mm2).
Selection, Scoring, and Confirmation of the
Predictor
The first concern was to identify the most objective
histologic parameters so as to minimize interobserver
Table 1. Clinicopathologic Characteristics of the 940






Total population 328 (100) 612 (100)
Center
Bari 328 (100) —
Milan — 79 (12.9)
Modena — 255 (41.7)
Padua — 69 (11.3)
Turin — 209 (34.2)
Period of diagnosis
<2000 140 (42.7) 69 (11.3)
2000–2004 64 (19.5) 106 (17.3)
2005–2009 59 (18.0) 161 (26.3)
2010 65 (19.8) 276 (45.1)
Sex
Male 247 (75.3) 450 (73.5)
Female 81 (24.7) 162 (26.5)
Age at diagnosis, y
<60 81 (24.7) 125 (20.4)
60–69 104 (31.7) 202 (33.0)
70–79 108 (32.9) 223 (36.4)
80 35 (10.7) 62 (10.1)
Asbestos exposure
No 102 (31.1) 144 (23.5)
Yes 226 (68.9) 331 (54.1)
Missing cases — 137 (22.4)
Histologic variant
Epithelioid 221 (67.4) 478 (78.1)
Pattern mostly solid 148 (45.1) 214 (35.0)
Pattern mostly tubular 40 (12.2) 60 (9.8)
Pattern mostly papillary 6 (1.8) 135 (22.1)
Pattern mostly
microcystic
8 (2.4) 23 (3.8)
Pattern mostly Indian
files
19 (5.8) 46 (7.5)
Biphasic 73 (22.3) 84 (13.7)
Pattern mostly solid 61 (18.6) 60 (9.8)
Pattern mostly tubular 12 (3.7) 17 (2.8)




Sarcomatoid 34 (10.4) 50 (8.2)
Classic (high cellularity) 12 (3.7) 35 (70.0)
Classic (low cellularity) 8 (2.4) 2 (4.0)
Desmoplastic 8 (2.4) 11 (22.0)
Pleopmorphic 6 (1.8) 2 (4.0)
Nucleoli
Inconspicuous 23 (7.0) 290 (47.4)
Distinct 201 (61.3) 206 (33.7)
Macronucleolus 96 (29.3) 114 (18.6)
n/e (desmoplastic) 8 (2.4) 2 (0.3)
Atypia
Mild 16 (4.9) 173 (28.3)
Moderate 141 (43.0) 277 (45.3)
Severe 163 (49.7) 153 (25.0)









<10% 52 (15.9) 108 (17.6)
10%–19% 82 (25.0) 239 (39.1)
20%–29% 67 (20.4) 56 (9.2)
30% 127 (38.7) 187 (30.6)
Missing cases — 22 (3.6)
Mitosis number
1–2 50 (15.2) 187 (30.6)
3–5 140 (42.7) 211 (34.5)
6–9 99 (30.2) 120 (19.6)
10 39 (11.9) 94 (15.4)
Stage
I 52 (15.9) 2 (0.3)
II 51 (15.5) 8 (1.3)
III 28 (8.5) 18 (2.9)
IV 29 (8.8) 181 (29.6)
Missing cases 168 (51.2) 403 (65.8)
Chemotherapy
None 105 (32.0) 13 (2.1)
Palliative 223 (68.0) 242 (39.5)
Missing cases — 357 (58.3)
Sampling material
Small biopsy specimen 190 (57.9) 408 (66.7)
Large biopsy specimen
(pleurectomy)
107 (32.6) 183 (29.9)
Surgical specimen 31 (9.5) 21 (3.4)
Necrosis
Absent 247 (75.3) 415 (67.8)
Present 81 (24.7) 197 (32.2)
Ki-67 LI, Ki-67 labeling index; n/e, not evaluable.
--- 2018 Grading Malignant Pleural Mesothelioma 5variability of the defining criteria. Reproducibility testing
showed excellent agreement beyond chance for necrosis
(k ¼ 0.81), histologic subtyping (k ¼ 0.93), Ki-67 LI
(k ¼ 0.81), and mitotic count (k ¼ 0.76) but not nucleoli
(k ¼ 0.69) or cell atypia (k ¼ 0.66). Therefore, histologic
subtyping, necrosis, Ki-67 LI, and mitotic count entered
the prediction system for tumor grading (Supplementary
Table 1). Supplementary Table 2 presents the results of
univariate analysis for all variables and the results of the
multivariate analysis with consideration for the four
aforementioned histologic parameters. For the sake of
simplicity, we decided to group patients with BMPM
(regardless of the amount of sarcomatoid component or
other subtype), together with patients with EMPM
and patients with a Ki-67 LI less than 30%, as none of
these subgroups demonstrated significant differences
in survival.
Scoring attribution was performed in the training set
on the basis of HR, with 1 point awarded for the pres-
ence of necrosis (HR ¼ 1.60, 95% CI: ¼1.22–2.09), 2
points awarded for the SMPM histologic variant
Table 2. Histopathologic Traits Associated with Overall
Survival at Multivariate Analysis in the Training Cohort
(n ¼ 328 patients) and Assignation of Relative Points for




of PointsHR (95% CI)
Necrosis
Absent 1 0
Present 1.60 (1.22–2.09) 1
Histologic variant
Epithelioid/biphasic 1 0
Sarcomatoid 2.04 (1.39–2.99) 2
Ki-67 LI
<30% 1 0
30% 1.54 (1.19–2.00) 1
Mitosis number
1–2 1 0
3–5 1.90 (1.32–2.74) 1
6–9 2.79 (1.89–4.12) 2
10 4.26 (2.61–6.95) 4
Note: For details on the assessment of the defining criteria (necrosis, histo-
logic variant, Ki-67 LI, and mitosis number), see the Materials and Methods
section. Statistically significant HR values less than 2 are scored as 1 point,
HR values of 2 to 4 are scored as 2 points, and HR values greater than 4 are
scored as 4 points.
HR, hazard ratio; CI, confidence interval; KI-67 LI, Ki-67 labeling index.
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Ki-67 LI of at least 30% (HR ¼ 1.54, 95% CI: 1.19–2.00),
1 point awarded for a mitotic count of 3 to 5 (HR ¼ 1.90,
95% CI: 1.32–2.74), 2 points awarded for a mitotic count
of 6 to 9 (HR ¼ 2.79, 95% CI: 1.89–4.12), and 4 points
awarded for a mitotic count of 10 (HR ¼ 4.26, 95% CI:
2.61–6.95) (Table 2). The distribution of the resulting
score in the training cohort and in the validation cohort,
by center, is presented in Supplementary Table 3. The
prediction power of this multiparametric PGS compared
with that of the single-event evaluation was subse-
quently confirmed by the AUC receiver operating
characteristic analysis of the 12-month mortality rate,
which showed an AUC far wider for the PGS than that for
mitoses or the Ki-67 LI, as assessed separately in either
tumor set (Fig. 1). The integrated AUC for the PGS over
time was 0.761 in the training cohort and 0.731 in the
validation cohort (Fig. 2). There was a highly significant
correlation between Ki-67 LI and mitotic count in both
the training and validation sets (p < 0.0001), albeit with
a wide dispersion of values (Pearson correlation coeffi-
cient values of 0.41 and 0.35, respectively). A schematic
flowchart illustrating the development and validation of
this PGS is depicted in Supplementary Figure 1. Repre-
sentative histologic pictures of MPM cases according to
the four defining criteria being used in this study are
depicted in Supplementary Figure 2.
PGS score was demonstrated to be an excellent
prognostic factor in both the training and the validationsets (log-rank p < 0.0001) (Fig. 3). The risk of death
increased by 45% (training set) or 31% (validation set)
for a 1-point increase in the PGS score. After adjustment
for age at diagnosis and (when available) for tumor
stage, the respective HRs for a 1-point increase in PGS
score were 1.46 (95% CI 1.36–1.56) in the training set
and 1.28 (95% CI: 1.22–1.34) in the validation set. Pa-
tient survival progressively deteriorated from a score of
0 (median 26.3 and 26.9 months in the training and
validation sets, respectively) to a score of 1 to 3 (median
times of 12.8 and 14.4 months, respectively) and a score
of 4 to 8 (median times of 3.7 and 7.7 months, respec-
tively), with no heterogeneity across validation centers
in the death risk attribution (p ¼ 0.19) (see Fig. 3). The
predicted 12-month mortality derived from the Cox
model with the PGS score set as a continuous variable
showed a good concordance with the observed
12-month mortality obtained from actuarial survival
analysis (Fig. 4). When the prediction model derived
from the testing cohort was applied to the validation
cohort, the predicted 12-month mortality was again in
agreement with that observed (see Fig. 4).
With regard to the whole tumor series of 940
patients, there was a 34% increase in risk of death per
1-point increase in PGS score, with narrow 95% CIs
(Fig. 5). Such excess risk was present in all variables
under evaluation (center, sex, age, type of material, stage,
chemotherapy, and histologic subtyping); it was lower
only among patients unable to receive chemotherapy
and in those with sarcomatoid tumor. The excess risk
was also lower in patients with missing information
about stage (HR ¼ 1.29, 95% CI: 1.23–1.35) than in
those with available information (HR ¼ 1.42, 95% CI:
1.34–1.52), with a significant interaction (p ¼ 0.002)
between PGS score and stage missingness (see Fig. 5).
Similarly, the ability of the PGS score to predict
12-month mortality was high in all subgroups, with
AUCs around 0.70. Interestingly, PGS score was associ-
ated with deterioration of median survival of patients,
while increasing its value regardless of histologic variant
(Table 3).Discussion
In the recent past, several histologic traits have been
proposed as prognosticators in patients with pleural
or peritoneal malignant mesothelioma, including
Ki-67 LI,21,22,27 cell/nuclear atypia,22,26,30 nuclear-to-
cytoplasmic ratio,22 chromatin pattern,22 intranuclear
inclusions,22 nuclear grade/size,13,30 nucleolar promi-
nence,22,30 necrosis,29,30 (atypical) mitoses,13,22,26,28–30
lymphocyte infiltration,28 and growth pattern,28 mostly
being effective in EMPM. They have been considered only
as single or independent factors, with no interaction
Figure 1. Receiver operating characteristic curves with the relevant area under curve (AUC) for the pathologic grading
system, mitotic count, and Ki-67 LI as predictors of mortality at 12 months in the training and the validation cohorts of
patients. The AUC values for the pathologic grading system, mitotic count, and Ki-67 LI as predictors of 2-year and 5-year OS
were, respectively, 0.76, 0.71, and 0.69 and 0.85, 0.81, and 0.80 in the training cohort and 0.73, 0.72, and 0.64 and 0.73,
0.77, and 0.56 in the validation cohort.
--- 2018 Grading Malignant Pleural Mesothelioma 7analysis of variables or predictive evaluation for the type
of patient cancer. It is thus difficult to attribute to these
parameters a decision-making role in the clinical work-up
of patients with MPM once tumors have been diagnosed
on the basis of biopsy samples or surgical specimens so as
to plan the subsequent clinical handling. A recent inter-
action analysis of prognostic variables in risk groups of
patients with MPM has taken into account histologic
subtyping solely among pathologic factors,8 with the
result that the clinical request for an effective PGS con-
tinues to remain an unanswered question.1,8,9,15–17,19
The goal of this study was to set up a PGS for use in
patients with MPM that is able to identify tumor
aggressiveness in the individual patient as exemplified
by median survival thresholds according to different
scores obtained by using a combination of mitotic count,
Ki-67 LI, necrosis, and histologic subtyping.34 We did not
include any molecular information because we wantedFigure 2. Time-dependent area under the curve (AUC) in the t
represents the 95% confidence intervals (CIs). Abbreviation: PGto create a simple, reproducible, and inexpensive tool to
be applied anywhere to help clinicians in patient man-
agement. Accordingly, we assembled the largest series of
patients with MPM thus far investigated for grading
purposes, which was labeled as a training cohort to fit
the model (the Bari set), and a validation cohort to
confirm the validity of the proposed model (the Milan,
Modena, Padua, and Turin sets). An interobserver
agreement test served to select the most reproducible
variables to insert in the prediction model. For the
construction of a widespread prediction model, we took
into consideration only those histopathologic parameters
that show good reproducibility between centers/pa-
thologists and are well-known parameters by most
pathologists.
Of note, the four parameters fitting the model are
widely known by pathologists faced with malignant
mesothelioma, either pleural or peritoneal,13,21,22,26–30raining cohort and in the validation cohort. The shaded area
S, pathologic grading system.
Figure 3. Overall survival after diagnosis of malignant pleural mesothelioma according to the pathologic grading system
(PGS) in the training and the validation cohorts of patients. There was 31% to 45% death risk increase for every 1-point
increment of the hazard ratio (HR) values, and median survival deteriorated over time according to the increase in PGS
scoring. The Milan HR value was 1.19 (95% confidence interval [CI]: 1.06–1.34); the Modena HR value was 1.31 (95% CI: 1.23–
1.41); the Padua HR value was 1.39 (95% CI: 1.17–1.65); and the Turin HR value was 1.39 (95% CI: 1.28–1.52); no heterogeneity
was observed across the four validation centers (p ¼ 0.19).
8 Pelosi et al Journal of Thoracic Oncology Vol. - No. -but only those showing excellent agreement beyond
chance (k score >0.75) eventually entered the predictor.
Cell atypia30 and prominence of nucleoli, which have
been used in other studies,13,22,30 were discarded inas-
much as the relevant k value indicated only a good
agreement beyond chance. We chose to assess interob-
server rather than intraobserver agreement35 for all
potentially eligible variables because they should have
been of clinical help in the practical management of
patients with MPM.
The mitotic count was quantified per 1 mm2 for a
quick and easy assessment and hence was more prac-
tical than the system based on the evaluation of larger
tumor areas,22,26 also considering the well-known
plateau effect when cell counting is expanded toFigure 4. Calibration of the predicted 12-month mortality
predicted 12-month mortality is derived from a univariate Co
cohort, with the pathologic grading system score set as a c
survival estimate is S0 ¼ 0.73840 [for a subject with a patholarger tumor areas34 and there is some variability in
the definition of high-power microscopic fields.22
Furthermore, guidelines in assessing mitoses in
malignant mesothelioma are still lacking.7,31,36 We
evaluated Ki-67 LI on hot spot areas by counting 2000
cells or 1 mm2 in the same tumor block and areas as
mitotic count for the sake of comparison because this
numeric value averaged 4.5 quantified fields each
measuring 0.237 mm2 (microscopic diameter 0.55
mm).34 This procedure has been shown to provide
reproducible results in biopsy samples and paired
surgical specimens of lung neuroendocrine neoplasms,
which are comparable in terms of tumor cellularity,
also confirming the Ki-67 LI plateau effect during
evaluation of larger tumor surfaces.34,37in the training cohort and in the validation cohort. The
x proportional hazard regression model fitted in the testing
ontinuous variable (1-S0
exp(0.37086*PGS), where the baseline




the Curve HR (95% CI) for 1-Point Increase HR (95% CI)0 1–3 ≥4
n (%) n (%) n (%)
All patients 142 (15.1) 596 (63.4) 202 (21.5) 0.74 1.34 (1.30–1.39)
Center
Bari 31 (  9.5) 228 (69.5) 69 (21.0) 0.76 1.45 (1.35–1.55)
Milan 14 (17.7) 36 (45.6) 29 (36.7) 0.62 1.19 (1.06–1.34)
Modena 6 (  2.4) 187 (73.3) 62 (24.3) 0.73 1.31 (1.23–1.41)
Padua 13 (18.8) 42 (60.9) 14 (20.3) 0.74 1.39 (1.17–1.65)
Turin 78 (37.3) 103 (49.3) 28 (13.4) 0.66 1.39 (1.28–1.52)
Sex
Male 135 (15.7) 537 (62.5) 187 (21.8) 0.74 1.34 (1.29–1.39)
Female 7 (  8.6) 59 (72.8) 15 (18.5) 0.75 1.45 (1.27–1.65)
Age, y
<60 43 (20.9) 129 (62.6) 34 (16.5) 0.74 1.41 (1.29–1.53)
60–69 51 (16.7) 211 (69.0) 44 (14.4) 0.73 1.44 (1.34–1.56)
70–79 42 (12.7) 191 (57.7) 98 (29.6) 0.75 1.30 (1.23–1.37)
≥80 6 (  6.2) 65 (67.0) 26 (26.8) 0.68 1.17 (1.04–1.31)
Sampling material
Small biopsy specimen 94 (15.7) 385 (64.4) 119 (19.9) 0.76 1.38 (1.32–1.45)
Large biopsy specimen 33 (11.4) 181 (62.4) 76 (26.2) 0.7 1.29 (1.21–1.38)
Surgical specimen 15 (28.9) 30 (57.7) 7 (13.5) 0.76 1.28 (1.04–1.58)
Stage
I 6 (11.1) 36 (66.7) 12 (22.2) 0.9 1.53 (1.29–1.83)
II 9 (15.3) 44 (74.6) 6 (10.2) 0.74 1.36 (1.11–1.66)
III 16 (34.8) 21 (46.7) 9 (19.6) 0.81 1.48 (1.23–1.78)
IV 65 (31.0) 109 (51.9) 36 (17.1) 0.75 1.40 (1.29–1.52)
Missing 46 (  8.1) 386 (67.6) 139 (24.3) 0.72 1.29 (1.23–1.35)
Chemotherapy
None 2 (  1.7) 60 (50.9) 56 (47.5) 0.87 1.05 (0.96–1.13)
Palliative 35 (  7.5) 355 (76.3) 75 (16.1) 0.7 1.33 (1.26–1.41)
Missing 105 (29.4) 181 (50.7) 71 (19.9) 0.72 1.31 (1.23–1.39)
Histologic variant
Epithelioid 134 (19.2) 487 (69.7) 78 (11.2) 0.69 1.38 (1.31–1.45)
Mostly solid 47 (13.0) 257 (71.0) 58 (16.0) 0.72 1.39 (1.29–1.50)
Mostly nonsolid 87 (25.8) 230 (68.3) 20 (  5.9) 0.62 1.32 (1.21–1.44)
Biphasic 8 (  5.1) 84 (53.5) 65 (41.4) 0.69 1.24 (1.13–1.36)
Mostly solid 5 (  4.1) 63 (52.1) 53 (43.8) 0.66 1.24 (1.11–1.38)
Mostly nonsolid 3 (  8.3) 21 (58.3) 12 (33.3) 0.81 1.40 (1.13–1.73)
Sarcomatoid — 25 (29.8) 59 (70.2) 0.55 1.10 (0.99–1.23)
1.00        1.25        1.50      1.75      
HR value
Figure 5. Stratified analysis by forest plot of scoring pathologic grading system for several variables along with area under
the curve evaluation for each variable being investigated. HR, hazard ratio; 95% CI, 95% confidence interval.
--- 2018 Grading Malignant Pleural Mesothelioma 9It could be said that the more cells that were counted,
the more interobserver differences were minimized until
a plateau effect was reached, after which the results no
longer changed. These considerations may explain why
our predictor was somewhat independent of the mate-
rial being analyzed, as was recently noted by others,30
also suggesting a minor intratumor behavioralTable 3. Numbers of Patients and Their Median Overall




Median Overall Survival, mo (95% CI)
Score 0 Score 1–3 Score 4
















Note: The testing and validation cohorts have been combined.
CI, confidence interval.heterogeneity of MPM despite its claimed polyclonal
origin38 and genetic complexity.39,40 Furthermore, we
chose to count cells with a manual counter rather than
by using automated analysis systems so as to make re-
sults more applicable in daily practice, where automated
imaging systems can be inaccessible or cumbersome.
The close association between mitotic count and
Ki-67 with a relatively low coefficient indicative of wider
dispersion of values was largely expected, as these
biomarkers are related to different measures of cell
cycle.41–43 The combined use of both proliferation
indices can compensate for assessment errors in either
parameter, as suggested in other tumor grading systems
based on mitoses and Ki-67 LI simultaneously.44,45
Histologic subtyping is currently considered the
single most important parameter and basically repre-
sents the main contribution of pathology alongside
tumor staging to the clinical work-up of malignant
mesothelioma7,13,21,22,26–30 and related clinical predic-
tion models,1,2,8,9,15–17,19 whether pleural or peritoneal.
Accordingly, this criterion was considered a backbone
10 Pelosi et al Journal of Thoracic Oncology Vol. - No. -of the PGS. As the amount of the sarcomatoid compo-
nent has been said to be relevant to prognosis of
BMPM,7,31 we investigated these tumors in a pre-
liminary analysis of the testing cohort according to the
amount of sarcomatoid component (data not shown).
In 29 out of 73 patients with BMPM, the tumor was
mostly epitheliod and in 44 it was mostly sarcomatoid.
At univariate analysis, patients with mostly BMPM had
a risk of death similar to that in patients with EMPM
(HR ¼ 1.22, 95% CI: 0.82–1.83), whereas patients with
mostly sarcomatoid biphasic tumor had an increased
risk of death somewhat similar to that in patients with
pure sarcomatoid tumor (HR ¼ 2.27, 95% CI: 1.63–
3.17). However, in a fully adjusted model (for age,
necrosis, tumor grade, nucleoli, cell atypia, Ki67, p16
alterations by fluorescence in situ hybridization,
mitotic count, and tumor stage) this association for
patients with mostly sarcomatoid BMPM lost any sta-
tistical significance (HR ¼ 1.31, 95% CI: 0.91–1.87),
whereas it remained strong and significant for pure
SMPM (HR ¼ 2.29, 95% CI: 1.43–3.65). Accordingly
and for the sake of simplicity, we decided to regroup
patients with epithelioid and biphasic tumors together,
thereby assigning 2 points for PGS score only to pa-
tients with pure SMPM.
Necrosis in turn has been only occasionally
addressed as a prognosticator in MPM, having a negative
impact on prognosis alone or along with nuclear
grade.13,29,30 In our study, necrosis was the least
powerful prognosticator in both the training and vali-
dation sets, likely because of some colinearity with mi-
toses and Ki-67 LI as a reflection of disturbed growth in
cell proliferation-deregulated tumors.46 Nonetheless, it
was considered in the final model, as it contributed to
forecasting prognosis deterioration independently of the
other parameters.
The multiparametric approach of this PGS is the
first innovative approach to prognosis assessment of
MPM because it was based on the evaluation of
reproducible histopathologic factors and provided in-
formation on specific cancers. As a matter of fact, we
noticed steady deterioration of survival in both patient
cohorts for each point increase in the PGS score. As an
example, the median survival of patients in the vali-
dation set dropped from 26.9 months to 14.4 months
and 7.7 months with PGS scores of 0, 1 to 3, and 4 to 8,
respectively (see Fig. 2). The different institutions did
not affect the validation results, thus further stressing
the robustness and reproducibility of our four-tiered
histologic model with which results were obtained by
four independent pairs of pathologists. Stratification
analysis based on the whole series of 940 tumors again
confirmed a steady progression of risk of death as a
function of scoring. Some apparent discrepanciesemerging from the sensitivity analyses likely reflected
minor representation of aggressive MPM in some vali-
dation centers (e.g., the Milan set had a minor presence
of BMPM and SMPM, elderly patients suffering from
comorbidities, no chemotherapy treatment in patients
with poor performance status, and the well-known
rarity of SMPM [84 of 940 (8.9%)] in our study)
compared with the representation of other histologic
subtypes.7,31,36
A limitation of our study could be the lack of infor-
mation on tumor staging in a large proportion of patients
(about 60%). This should not have played a decisive role
in influencing the results, as the association between PGS
score and OS was present and statistically significant
both in patients with defined stage and in those with
missing stage, although it was weaker among patients
with missing stage (interaction p ¼ 0.002). Even so, this
consideration leaves open the interpretation that tumor
stage actually represents the final clinical outcome ac-
cording to duration of the preclinical phase, which in
turn is likely to temporally depend on the intrinsic
aggressiveness of individual tumors.
Thus far, the histologic subtypes of MPM have been
considered monolithic entities for clinical strategies to
manage, with a case mix of diversely surviving patients
still obvious in the epidemiologically prevalent epithe-
lioid subtype, to the extent that BMPM and SMPM are
often merged as nonepithelioid tumors for cumulative
risk of death to assess.1,2,7,18 Of note, our PGS was also
effective in subgroup analysis of MPM, in which similar
survival was seen across different histologic subtypes
according to the increase in PGS score, thus sustaining
once again the validity of the model. Other potentially
interfering factors for either biological or methodological
issues, such as chemotherapy administration, tumor
staging, and histologic subtyping within the categories
EMPM and BMPM, did not significantly affect the attri-
bution of risk of death and survival according to our
prediction model.
The precise position of a PGS in the clinical scenario
of patients with MPM is still unclear,1,2,7 but our
evidence-based PGS dissecting tumor aggressiveness in
different forms of MPM could also be a useful model to
enroll patients for chemoradiotherapy, target treat-
ments or surgery and palliation, plan follow-up
strategies, complement predictive and prognostic
molecular information, and design innovative
clinical trials based on a managerial vision of such a
disease.
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